The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
Commentary|Articles|December 8, 2025
Experts Highlight HR+ and TNBC Trials to Watch Ahead of SABCS 2025
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Leading clinicians preview anticipated HR+ and TNBC studies at SABCS 2025.
Advertisement
Advertisement
As anticipation builds for the 2025 San Antonio Breast Cancer Symposium (SABCS), OncLive® asked leading breast cancer specialists to share the hormone receptor (HR)–positive and triple-negative breast cancer (TNBC) presentations they are most eager to follow at this year’s meeting.
Related to this article
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Advertisement
Advertisement